[go: up one dir, main page]

EA200901442A1 - Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах - Google Patents

Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах

Info

Publication number
EA200901442A1
EA200901442A1 EA200901442A EA200901442A EA200901442A1 EA 200901442 A1 EA200901442 A1 EA 200901442A1 EA 200901442 A EA200901442 A EA 200901442A EA 200901442 A EA200901442 A EA 200901442A EA 200901442 A1 EA200901442 A1 EA 200901442A1
Authority
EA
Eurasian Patent Office
Prior art keywords
adpt
expresse
thrombocytes
activity
compounds
Prior art date
Application number
EA200901442A
Other languages
English (en)
Other versions
EA020045B1 (ru
Inventor
Памела Б. Конли
Патрик Андре
Ума Синха
Original Assignee
Портола Фармасьютиклз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Портола Фармасьютиклз, Инк. filed Critical Портола Фармасьютиклз, Инк.
Publication of EA200901442A1 publication Critical patent/EA200901442A1/ru
Publication of EA020045B1 publication Critical patent/EA020045B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим композициям и способам комбинированной терапии, включающей [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2Н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевину или ее фармацевтически приемлемую соль, для лечения тромбозных заболеваний.
EA200901442A 2007-05-02 2008-05-02 Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах EA020045B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US91591107P 2007-05-03 2007-05-03
US94792107P 2007-07-03 2007-07-03
US97870007P 2007-10-09 2007-10-09
PCT/US2008/062561 WO2008137787A2 (en) 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet adp receptor inhibitor

Publications (2)

Publication Number Publication Date
EA200901442A1 true EA200901442A1 (ru) 2010-06-30
EA020045B1 EA020045B1 (ru) 2014-08-29

Family

ID=39587017

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901442A EA020045B1 (ru) 2007-05-02 2008-05-02 Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах

Country Status (20)

Country Link
US (2) US20080279845A1 (ru)
EP (2) EP2586439A1 (ru)
JP (1) JP5439363B2 (ru)
KR (1) KR101509829B1 (ru)
CN (1) CN101686959B (ru)
AU (1) AU2008247435A1 (ru)
BR (1) BRPI0811000A2 (ru)
CA (1) CA2684722A1 (ru)
CO (1) CO6241105A2 (ru)
EA (1) EA020045B1 (ru)
EC (1) ECSP099775A (ru)
ES (1) ES2467468T3 (ru)
GT (1) GT200900283A (ru)
IL (1) IL201826A (ru)
MA (1) MA31396B1 (ru)
MX (1) MX2009011755A (ru)
NZ (2) NZ599556A (ru)
PT (1) PT2146705E (ru)
TN (1) TN2009000444A1 (ru)
WO (1) WO2008137787A2 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1259485T3 (da) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
BRPI0512273A (pt) * 2004-06-18 2008-02-19 Millennium Pharm Inc inibidores do fator xa
HUE032640T2 (en) 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
WO2007112367A2 (en) * 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
CA2651303A1 (en) 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
ES2550057T3 (es) 2006-11-02 2015-11-04 Millennium Pharmaceuticals, Inc. Métodos para sintetizar sales farmacéuticas de un inhibidor del Factor Xa
EP2114930A2 (en) * 2007-01-05 2009-11-11 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
WO2008127682A2 (en) 2007-04-13 2008-10-23 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
ES2611077T3 (es) 2007-12-07 2017-05-04 Vertex Pharmaceuticals Incorporated Forma solida de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamida)-3-metilpiridin-2-il) benzoico
AR074347A1 (es) * 2008-11-14 2011-01-12 Portola Pharm Inc Composicion solida para liberacion controlada de agentes activos ionizables con solubilidad acuosa deficiente a ph bajo y sus metodos de uso
WO2011075602A1 (en) 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
WO2011084652A2 (en) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor
WO2011076749A2 (en) * 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form
WO2011089168A2 (fr) * 2010-01-21 2011-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Composition particuliere pour son application comme medicament
DK2538925T3 (en) * 2010-02-25 2016-03-14 Bristol Myers Squibb Co Apixabanformuleringer
ES2604480T5 (es) 2010-04-07 2020-03-17 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
TW201221128A (en) 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
HRP20150613T1 (hr) * 2011-03-29 2015-07-17 Sanofi Sol benzojeve kiseline otamiksabana
WO2013033370A1 (en) * 2011-08-31 2013-03-07 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
EP2934538B1 (en) 2012-12-19 2021-03-31 Merck Sharp & Dohme Corp. Factor ixa inhibitors
EP2934537B1 (en) * 2012-12-19 2018-04-04 Merck Sharp & Dohme Corp. Factor ixa inhibitors
US9695198B2 (en) 2012-12-19 2017-07-04 Merck Sharp & Dohme Corp. Factor IXa inhibitors
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
SI3068392T1 (sl) 2013-11-12 2021-07-30 Vertex Pharmaceuticals Incorporated Postopek za pripravo farmacevtskih sestavkov za zdravljenje bolezni, ki jih posreduje CFTR
US9676723B2 (en) * 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
CN106831553A (zh) * 2015-09-11 2017-06-13 天津科伦药物研究有限公司 贝曲西班或其类似物的制备方法
CN105250286A (zh) * 2015-11-13 2016-01-20 谭惠娟 一种抗血栓组合物
EP3254674A1 (en) * 2016-06-08 2017-12-13 Sandoz Ag Pharmaceutical compositions of betrixaban maleate
US10875851B2 (en) 2016-11-18 2020-12-29 Merck Sharp & Dohme Corp. Factor XIIa inhibitors
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440147B1 (en) * 1998-09-03 2002-08-27 Rubicor Medical, Inc. Excisional biopsy devices and methods
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6297233B1 (en) 1999-02-09 2001-10-02 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
KR100760434B1 (ko) 1999-09-17 2007-10-04 밀레니엄 파머슈티컬스 인코퍼레이티드 벤즈아미드 및 관련된 Ｘａ 인자의 억제제
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
DK1259485T3 (da) * 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
US7235567B2 (en) 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
EP1330544A4 (en) 2000-09-26 2005-04-06 Univ Duke RNA APTAMERS AND METHOD OF IDENTIFYING SAID APTAMERS
US7312235B2 (en) * 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
CN1780823A (zh) * 2003-04-09 2006-05-31 日本烟草产业株式会社 杂芳族五环化合物及其医药应用
JP4879745B2 (ja) * 2003-10-03 2012-02-22 ポートラ ファーマシューティカルズ， インコーポレイテッド 置換イソキノリノン
CN1886398A (zh) * 2003-10-09 2006-12-27 米伦纽姆医药公司 作为Xa因子抑制剂的经硫醚取代的苯甲酰胺
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
BRPI0512273A (pt) * 2004-06-18 2008-02-19 Millennium Pharm Inc inibidores do fator xa
WO2006045756A1 (en) * 2004-10-25 2006-05-04 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
EP1844002A1 (en) 2005-02-02 2007-10-17 Vitae Pharmaceuticals, Inc. 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
US7467697B2 (en) * 2005-10-07 2008-12-23 Ford Global Technologies, Llc Electromagnetic coupling device for engine accessories
US20070208045A1 (en) * 2005-11-03 2007-09-06 Portola Pharmaceuticals, Inc. Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof
DK1948608T3 (da) * 2005-11-08 2012-07-02 Millennium Pharm Inc Farmaceutiske salte og polymorfe former af N-(5-chlor-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]-benzoyl]amino]-5-methoxybenzamid, en faktor xa-inhibitor
WO2007112367A2 (en) 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
CA2651303A1 (en) * 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
CA2913963A1 (en) * 2006-12-08 2008-06-19 Millenium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
EP2114930A2 (en) * 2007-01-05 2009-11-11 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
WO2008127682A2 (en) * 2007-04-13 2008-10-23 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor

Also Published As

Publication number Publication date
US20110033459A1 (en) 2011-02-10
CO6241105A2 (es) 2011-01-20
BRPI0811000A2 (pt) 2015-01-27
AU2008247435A1 (en) 2008-11-13
GT200900283A (es) 2011-10-05
EP2146705B1 (en) 2014-03-05
EA020045B1 (ru) 2014-08-29
JP2010526103A (ja) 2010-07-29
WO2008137787A3 (en) 2009-02-05
TN2009000444A1 (en) 2011-03-31
MA31396B1 (fr) 2010-05-03
NZ581324A (en) 2012-05-25
EP2146705A2 (en) 2010-01-27
CA2684722A1 (en) 2008-11-13
EP2586439A1 (en) 2013-05-01
CN101686959B (zh) 2014-05-07
KR20100023836A (ko) 2010-03-04
JP5439363B2 (ja) 2014-03-12
KR101509829B1 (ko) 2015-04-06
ES2467468T3 (es) 2014-06-12
HK1138765A1 (en) 2010-09-03
WO2008137787A2 (en) 2008-11-13
IL201826A0 (en) 2010-06-16
US20080279845A1 (en) 2008-11-13
MX2009011755A (es) 2010-02-12
US8946219B2 (en) 2015-02-03
IL201826A (en) 2014-08-31
CN101686959A (zh) 2010-03-31
PT2146705E (pt) 2014-05-23
ECSP099775A (es) 2010-01-29
NZ599556A (en) 2013-10-25

Similar Documents

Publication Publication Date Title
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201070786A1 (ru) Бензофуропиримидиноны
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
EA200901486A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
UA108087C2 (ru) Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида
JO2885B1 (en) Protein kinase inhibitors
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA200970946A1 (ru) Комбинированная терапия антикоагулирующего средства с соединением, которое действует как ингибитор фактора ха
UA115320C2 (uk) Інгібітори кінази
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA201691759A1 (ru) Композиции и способы лечения легочной гипертензии
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU